FDA Grants Authorization to Epiminder’s Implantable Continuous EEG Monitor for Epilepsy Treatment

With U.S. HQ in Dallas, Epiminder Gets FDA Authorization for Implantable Monitor for Epilepsy Patients

Dallas Innovates, Every Day: Here's what's new + next in North Texas. Melbourne, Australia-based medical device company Epiminder—which has its U.S. headquarters in Dallas—has been granted FDA authorization via the De Novo classification for Minder, the company’s proprietary implantable continuous electroencephalogram monitoring system (iCEMTM) for patients with epilepsy. Minder has also been designated as a Breakthrough Technology by the FDA, r…

FDA Grants Authorization to Epiminder’s Implantable Continuous EEG Monitor for Epilepsy Treatment

The system has been previously recognized with breakthrough device designation by the FDA, emphasizing its potential to enhance epilepsy care through more effective diagnosis and management.

Caring For A Loved One With Epilepsy

Dhaval’s StoryJignesh* is a 38-year-old, first-generation immigrant from India who owns a motel in the Midwest. His wife, Hansaben, * is a 34-year-old homemaker. They immigrated to the US about 10 years back and have a son, Dhaval, * who is 11 years old and goes to school. Recently, a rather Dhaval experienced unusual movements of the body, and lost consciousness for a few minutes.   He recovered from this episode of unconsciousness but said he …

Epiminder’s implantable EEG system for epilepsy receives FDA authorisation

Epiminder has received FDA authorisation through the De Novo classification for its implantable continuous EEG monitoring system, Minder.The post Epiminder’s implantable EEG system for epilepsy receives FDA authorisation appeared first on Medical Device Network.